Bottom line: In early 2025 the RYBREVANT label tightened safety language (notably infusion-related reactions, anaphylaxis placement, and venous thromboembolism management with lazertinib) and clarified dosing/administration details. Later in 2025, FDA accepted a supplement to update overall survival results from MARIPOSA, which will flow into Clinical Studies once the updated PI posts. Together, these moves round out a maturing label across four NSCLC indications.
The approved uses at a glance (no changes to the four core indications)
RYBREVANT remains indicated for adults with locally advanced/metastatic NSCLC across four EGFR-defined settings:
- First-line, EGFR Ex19del/L858R: RYBREVANT + lazertinib.
- Post-TKI, EGFR Ex19del/L858R: RYBREVANT + carboplatin + pemetrexed.
- First-line, EGFR exon 20 insertion: RYBREVANT + carboplatin + pemetrexed.
- Post-platinum, EGFR exon 20 insertion: RYBREVANT monotherapy. FDA Access Data
“Recent Major Changes” in the current PI highlight that Indications & Usage last changed in 09/2024, while Dosage & Administration and Warnings & Precautions were updated in 02/2025—the period relevant to this article. FDA Access Data
What changed in 2025: the safety and administration pieces you’ll actually use
1) Infusion-related reactions (IRR) and anaphylaxis now clearly flagged
- The PI emphasizes split dosing in Week 1 (Day 1 & Day 2) and peripheral-line administration during Weeks 1–2 to lower early IRR risk.
- At the first sign of IRR, interrupt the infusion; depending on severity, reduce rate or permanently discontinue.
- In February 2025, FDA approved a safety supplement explicitly adding “anaphylaxis” across key sections (Dosage Modifications, Warnings & Precautions, Postmarketing, Counseling, and PPI). This elevates vigilance and documentation in infusion suites. FDA Access Data+1
Practical take: keep rescue meds at hand, staff to early-recognize Grade ≥2 IRR, and pre-brief patients. Confirm your center’s order sets mirror the label’s Dosage Modifications (2.6) language. FDA Access Data
2) VTE risk with lazertinib: prophylaxis becomes standard in months 0–4
- When RYBREVANT is given with lazertinib, the PI now calls for prophylactic anticoagulation for the first four months.
- If VTE occurs, withhold both agents based on severity, treat the VTE, and once anticoagulation is therapeutic, resumption is at clinician discretion; permanent discontinuation of RYBREVANT is advised for recurrent VTE despite therapeutic anticoagulation (lazertinib may continue). FDA Access Data
Practical take: assess baseline VTE risk, choose a prophylaxis strategy (e.g., DOAC vs LMWH per institutional policy), and document a plan for imaging thresholds and drug holds in the first 120 days.
3) Dosing & administration clarity you’ll reference every week
- Weight-based dosing using the 80-kg threshold remains, but the PI consolidates how, when, and in what sequence to infuse in combinations:
- Chemo combo (carbo/peme): infuse pemetrexed first, carboplatin second, RYBREVANT last.
- Lazertinib combo: give lazertinib orally before the infusion.
- Schedules:
- Chemo combo: weekly ×4 (split dose in Week 1), then q3w starting Week 7.
- Lazertinib combo or monotherapy: weekly ×5 (split dose in Week 1), then q2w starting Week 7.
- Premeds are required; follow the PI tables for infusion rates (Tables 8 and 9). FDA Access Data
Practical take: build templated order sets that embed sequence (peme → carbo → RYBREVANT), premed timing, split-dose nursing tasks in Week 1, and a VTE prophylaxis default when lazertinib is co-administered.
4) Other key warnings you should keep top-of-mind
- ILD/pneumonitis: withhold for suspicion; permanently discontinue if confirmed.
- Dermatologic AEs: spectrum includes TEN and acneiform dermatitis; follow labeled hold/reduce/stop rules.
- Ocular toxicity: prompt ophthalmology referral for worsening symptoms; manage with holds/dose changes as directed.
- Embryo-fetal toxicity: contraception counseling is required. FDA Access Data
Clinical studies the label ties to each setting
- MARIPOSA (14.1): first-line Ex19del/L858R with lazertinib.
- MARIPOSA-2 (14.2): post-TKI Ex19del/L858R with carbo/peme.
- PAPILLON (14.3): first-line EGFR exon 20 insertion with carbo/peme.
- CHRYSALIS (14.4): post-platinum exon 20 insertion monotherapy. FDA Access Data
In August 2025, FDA approved a supplement to update the final overall survival analysis from MARIPOSA (a post-marketing commitment). As FDA finalizes the PI posting, expect the OS readout to be reflected under Clinical Studies 14.1. Build this into your patient-counseling and payer discussions once the PDF refresh is live. FDA Access Data
Why these 2025 changes matter
- Safety governance: Elevating anaphylaxis and tightening VTE language codifies what many centers already practice—and reduces variability in early-cycle care. FDA Access Data+1
- Operational clarity: The label now reads like a playbook—from split infusions to drug order within combination regimens—cutting down on infusion-chair delays and phone-a-pharmacist moments. FDA Access Data
- Evidence maturity: With OS updates incoming from MARIPOSA, clinicians will have more complete survival context when weighing lazertinib + RYBREVANT as first-line standard for common sensitizing EGFR mutations. FDA Access Data
Implementation checklist for clinics
- Update standing orders to include: split dosing, peripheral line Weeks 1–2, premeds, and infusion rates per Tables 8–9.
- Add a default VTE prophylaxis order set for any patient starting RYBREVANT + lazertinib (first 4 months).
- Refine your IRR algorithm with a distinct branch for suspected anaphylaxis.
- Refresh patient handouts for rash/eye symptoms and embryo-fetal risk.
- Flag your pathways to incorporate MARIPOSA OS once the updated PI PDF posts. FDA Access Data+1
Source notes
- Current (Feb 2025) RYBREVANT Prescribing Information—Highlights show the recent major changes; sections 1–2–5 carry the 02/2025 updates; dosing, VTE prophylaxis with lazertinib, IRR handling, ILD, dermatologic and ocular toxicity language are all present. FDA Access Data+1
- Supplement S-007 (Feb 2025): FDA letter confirming anaphylaxis added across labeling sections. FDA Access Data
- Supplement S-009 (Aug 2025): FDA letter approving final OS analysis from MARIPOSA for incorporation into labeling. FDA Access Data
Discover more from सुदर्शन
Subscribe to get the latest posts sent to your email.